- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Emerging strategies in BRCA-positive pancreatic cancer ; volume:144 ; number:8 ; day:18 ; month:5 ; year:2018 ; pages:1503-1507 ; date:8.2018
Journal of cancer research and clinical oncology ; 144, Heft 8 (18.5.2018), 1503-1507, 8.2018
- Creator
-
Kowalewski, Adam
- Contributor
-
Szylberg, Łukasz
Saganek, Michał
Napiontek, Wojciech
Antosik, Paulina
Grzanka, Dariusz
SpringerLink (Online service)
- DOI
-
10.1007/s00432-018-2666-9
- URN
-
urn:nbn:de:101:1-2018091801313555125965
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kowalewski, Adam
- Szylberg, Łukasz
- Saganek, Michał
- Napiontek, Wojciech
- Antosik, Paulina
- Grzanka, Dariusz
- SpringerLink (Online service)
Other Objects (12)
Risk Reduction Strategies in BRCA Patients: An Indian Perspective
Providers’ perspectives on the reproductive decision-making of BRCA-positive women
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
Kosteneffektivität von Talazoparib bei der Behandlung von fortgeschrittenem BRCA-positivem Mammakarzinom in Deutschland
BRCA-assoziierter Brustkrebs : erblicher Brustkrebs: was Sie über die BRCA Muttaion wissen müssen
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
BRCA Testing in Serbia and Montenegro
Market entry strategies for emerging economies
Die Patentierung von Krankheitsgenen : dargestellt am Beispiel der Patentierung der Brustkrebsgene BRCA 1 und BRCA 2
Emerging strategies in neuroprotection
Risk Reduction Strategies in BRCA Patients: An Indian Perspective
Providers’ perspectives on the reproductive decision-making of BRCA-positive women
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
Kosteneffektivität von Talazoparib bei der Behandlung von fortgeschrittenem BRCA-positivem Mammakarzinom in Deutschland
BRCA-assoziierter Brustkrebs : erblicher Brustkrebs: was Sie über die BRCA Muttaion wissen müssen
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
BRCA Testing in Serbia and Montenegro
Market entry strategies for emerging economies
Die Patentierung von Krankheitsgenen : dargestellt am Beispiel der Patentierung der Brustkrebsgene BRCA 1 und BRCA 2
Emerging strategies in neuroprotection
Risk Reduction Strategies in BRCA Patients: An Indian Perspective
Providers’ perspectives on the reproductive decision-making of BRCA-positive women
BRCA 1 and BRCA 2 tumor suppressors protect against endogenous acetaldehyde toxicity
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
Kosteneffektivität von Talazoparib bei der Behandlung von fortgeschrittenem BRCA-positivem Mammakarzinom in Deutschland
BRCA-assoziierter Brustkrebs : erblicher Brustkrebs: was Sie über die BRCA Muttaion wissen müssen
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
BRCA Testing in Serbia and Montenegro
Market entry strategies for emerging economies
Die Patentierung von Krankheitsgenen : dargestellt am Beispiel der Patentierung der Brustkrebsgene BRCA 1 und BRCA 2